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Abstract
Background: Adjuvant trastuzumab therapy has yielded conflicting results for overall survival, concerns about central
nervous system (CNS) metastasis, and questions about optimal schedule. Therefore, we carried out a meta-analysis to assess
the benefits of concurrent or sequential trastuzumab with adjuvant chemotherapy for early breast cancer patients with
HER2-positive tumors.
Methods: Computerized and manual searches were performed to identify randomized clinical trials comparing adjuvant
chemotherapy with or without trastuzumab in HER2-positive early breast cancer patients. Odds ratios were used to estimate
the association between the addition of trastuzumab to adjuvant chemotherapy and various survival outcomes. The fixed-
effects or random-effects model was used to combine data.
Findings: With six eligible studies identified, this analysis demonstrated that patients with HER2-positive breast cancer
derived benefit in disease-free survival, overall survival, locoregional recurrence and distant recurrence (all P,0.001) from
the addition of trastuzumab to adjuvant chemotherapy, whereas trastuzumab did worse in CNS recurrence as compared to
the control group (P=0.018). Furthermore, concomitant use of trastuzumab significantly lowered the hazard of death
(P,0.001) but bore a higher incidence of CNS recurrence (P=0.010), while statistical significance failed to be discerned for
either overall survival (P=0.069) or CNS metastasis (P=0.374) between the sequential and observation arms.
Conclusion: This analysis verifies the efficacy of trastuzumab in the adjuvant setting. Additionally, our findings indirectly
corroborate the superiority of concurrent trastuzumab to sequential use and also illuminate that prolonged survival is the
possible reason for the higher incidence of CNS with trastuzumab versus observation.
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Introduction
Over recent years, breast cancer remains the most common
cancer in women in western countries along with the sharp increase
in its incidence rate in developing countries [1]. By contrast, the
mortality rate has declined dramatically since the introduction of
adjuvant systemic therapy, which is now used extensively for its
established benefit in survival [2]. However, a considerable number
of patients experience disease progression despite optimal postop-
erative treatments, which hints at a demand for novel agents against
specific targets with greater efficacy and lesser toxicity [3].
Nowadays, an increasing number of targets have been yielded
through various drug discovery efforts and some of these
promising leads have moved beyond the stage of drug candidate,
as exemplified by human epidermal growth factor receptor 2
(HER2) and trastuzumab. HER2 protein, encoded by the HER2/
neu gene, belongs to a family of four homologous transmembrane
receptors involved in tyrosine kinase-mediated regulation of
normal breast tissue growth, differentiation, and survival.
Overexpression of the HER2/neu protein (immunohistochemistry
3+), amplification of the HER2/neu gene (fluorescence in situ
hybridization positive or chromogenic in situ hybridization
positive), or both accounts for approximately 20–25% of invasive
ductal carcinomas [4,5], which is associated with aggressive
clinical history in breast cancer patients. Trastuzumab, a
humanized monoclonal antibody blocking the HER2/neu recep-
tor, is one of the targeted approaches to reach the clinic for breast
cancer. Initially, trastuzumab demonstrated significant activity in
patients with HER2-positive metastatic breast cancer when
combined with chemotherapy [6]. Such compelling evidence
subsequently triggered the conduct of several large multicenter
randomized controlled clinical trials assessing sequential or
concurrent trastuzumab with chemotherapy in the adjuvant
setting. These impressive results have also unequivocally revealed
the striking effect of adjuvant trastuzumab on the improvement of
HER2-positive breast cancer prognosis.
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to trastuzumab administration after surgery. Firstly, the definitely
significant efficacy of trastuzumab was merely confined to the
primary endpoint, disease-free survival (DFS) [7–12], while
conflicting results were reported with regard to overall survival.
In the HERA trial, the 2-year follow-up report revealed that
adjuvant treatment with trastuzumab for 1 year lowered risk of
death by 34% as compared to the observation group, which
corresponded to an absolute overall survival benefit of 2.7% at 36
months with a statistically significant difference (P=0.0115) [11].
However, after a median follow-up of 4 years, the absolute
benefit in overall survival declined to 1.6% at 48 months and
statistical significance was not observed between the two groups
[7,12]. Some investigators argued that crossover to trastuzumab
of patients originally allocated to the observation arm might
disrupt and bias the intention-to-treat (ITT) comparison between
the 1-year trastuzumab and observation arms [7,12], but others
took issue with this line of thought since the findings from the
PACS 04 and FinHer studies revealed that adjuvant trastuzu-
mab did not affect overall survival despite the lack of crossover
[13–15]. Secondly, many oncologists reported frequent central
nervous system (CNS) metastasis during trastuzumab therapy in
several clinical trials [9,11,13–15], which has raised burning
concerns over the association of trastuzumab use with the
development of CNS recurrence. Thirdly, there is growing
attention toward how to optimize the combination of trastuzu-
mab with adjuvant chemotherapy. Updated results of the
NCCTG N9831 study demonstrated a strong trend for an
absolute benefit in DFS of 4.4% at 5 years with concomitant
trastuzumab relative to sequential administration (P=0.019).
Although this did not cross the boundary for statistical
significance (preset at 0.00116), investigators recommended
incorporation of adjuvant trastuzumab concurrent with the
taxane portion of chemotherapy [8]. Nevertheless, currently
available data are still not adequate to judge which schedule is
superior in efficacy, prompting further investigation for additional
evidence. Last but not least, relevant analyses from several large
randomized clinical trials have been much updated recently,
which makes it obliged to obtain the timely insight into a
paradigm shift in how we deal with HER2-positive breast cancer
patients in the adjuvant setting.
On account of the above points, we carried out a meta-analysis
to assess the prognostic effect of trastuzumab administration after
surgery in early breast cancer patients with HER2-positive tumors
so as to get a clear picture of the benefits it offers, providing the
implications for the appropriate use of trastuzumab in clinical
practice.
Methods
Publication search
The selection of publications for inclusion was performed
independently by two of the authors (Wenjin Yin and Yiwei Jiang),
with the last search on September 20, 2010. A computerized
search was performed through the PubMed database (from 1966
to the present), the online proceedings of the American Society of
Clinical Oncology (ASCO) Annual Meetings (years 1992–2010),
the online proceedings of the San Antonio Breast Cancer
Symposium (years 2004–2009), and the CD proceedings of the
International St. Gallen Breast Cancer Conference (years 2003–
2009), using the following search keywords: ‘‘trastuzumab’’ or
‘‘Hercetpin’’, ‘‘adjuvant’’ or ‘‘postoperative’’, and ‘‘breast cancer’’.
Manual searches were done by reviewing the reference lists of
retrieved studies, textbooks and review articles to identify
additional potentially eligible studies. The language of publication
was restricted to English.
Eligibility criteria
This analysis included all randomized controlled trials that
evaluated adjuvant chemotherapy with (concurrent or sequential)
or without the administration of trastuzumab at any dose and for
any duration among patients with HER2-positive invasive breast
cancer in the adjuvant setting. Interim analyses of trials or studies
presented in abstract form were considered eligible only if they
elucidated the latest available data on at least one of the endpoints
in this analysis. In case of multiple reports on the same trial arm,
the one with the longest follow-up interval was applied for the
calculations. Surgical modality, together with schemes of adjuvant
chemotherapy, radiotherapy and endocrine therapy, was not
considered for study selection. Trials were required not to test
trastuzumab as neoadjuvant or salvage treatment, as well as not to
evaluate biological response modifiers or targeted agents other
than trastuzumab.
Data extraction
The following information was extracted from each publication:
journal name, year of publication, first author, follow-up period,
number of patients analyzed per arm, chemotherapy and
trastuzumab regimens, and number of endpoint events per arm.
In the present analysis, two of the authors (Wenjin Yin and Yiwei
Jiang) independently extracted the information from each eligible
publication. All the relevant data were further reviewed by a third
investigator (Jinsong Lu) to reach consensus. No authors of the
original publications were contacted for verification or clarification
of their data.
Study endpoint
In this meta-analysis, the primary outcome was DFS, defined as
timefromrandomizationtothefirstoccurrenceofdiseaseprogression
or death from any cause without documentation of a cancer-related
event. Secondary outcomes included overall survival (death from any
cause), time to locoregional recurrence, time to distant recurrence,
time to contralateral breast cancer, and time to CNS recurrence.
Statistical analysis
All analyses were conducted according to the ITT principle.
Odds ratios (ORs) with their 95% confidence intervals (CIs) were
calculated from the number of outcome events per arm to estimate
the association between the addition of trastuzumab to adjuvant
chemotherapy and various survival outcomes. The heterogeneity
of the study results was assessed by Cochran chi-square Q statistics
and I-square test, which determined the use of either fixed-effects
(Mantel-Haenszel method) or random-effects (DerSimonian and
Laird method) model. Heterogeneity was considered as either a
P-value,0.05 or I-square.50% [16].
Funnel plots, contour-enhanced funnel plots, and Egger’s test
were used to evaluate the possible publication bias regarding each
study outcome. The fail-safe number was employed to estimate the
minimum number of ‘‘missing’’ studies averaging null results or no
effect that would be needed to overturn the conclusion reached in
the meta-analysis. Sensitivity analyses were conducted to assess the
influence of specific studies on the combined effect.
All tests were two-sided and P,0.05 was considered significant.
All statistical analyses were performed with Stata statistical
software package (release 10.0; Stata Corporation, College
Station, Texas, USA) and Comprehensive Meta-analysis software
program (Version 2.2.034, Biostat, Englewood NJ).
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Description of eligible studies
Based on the search strategy, six eligible studies were identified.
According to the timing of trastuzumab initiation with respect to
chemotherapy, all the trastuzumab arms from these trials were
categorized into the concurrent or sequential subgroup. The study
characteristics are summarized in Table 1.
From the HERA study, the efficacy of trastuzumab for 2 years
has not been reported, and therefore, this arm was excluded in this
analysis [7,11,12]. Additionally, the latest analysis of the NCCTG
N9831 study provided the results on the differences in DFS and
OS between the concurrent and sequential arm rather than those
between the concurrent and control arm [8]. By this token, the
concurrent arm was excluded from the meta-analysis.
As to the FinHer trial, only the data of HER2-positive patients
was extracted since it was a 262 study, where all the participants
were randomly assigned to receive three cycles of vinorelbine or
docetaxel, both followed by three cycles of fluorouracil, epirubicin
and cyclophosphamide (FEC), and then HER2-positive women
were further randomized to either trastuzumab or observation
[13,14].
When it came to the BCIRG 006 trial, controversies arose over
whether to incorporate the non-anthracycline, carboplatin-based
arm or not for the meta-analysis. Some investigators removed it for
lack of an appropriate unconfounded control [17,18]. However,
there is no denying the fact that the addition of trastuzumab to
docetaxel and carboplatin (DCarboT) was at least partially
responsible for its superiority in efficacy over the anthracycline-
based control arm on the basis of the available data. The exclusion
of the DCarboT arm might sacrifice valuable information. For the
sake of objective appraisal, the meta-analysis was conducted
respectively with or without subsuming the DCarboT arm.
It is noteworthy that as for site-specific recurrence there is a
distinction between events at any time and first events in this meta-
analysis. If both were available (only found in the PACS 04 trial
[15] concerning contralateral breast cancer), the former was
preferred to the latter; otherwise, first events served as a substitute
for events at any time.
Overall effect of trastuzumab on primary outcome
There was significant between-study heterogeneity (Table S1) in
the ORs for DFS (including the DCarboT arm of the BCIRG 006
trial, abbreviated to ‘‘DCarboT’’; heterogeneity chi-squared=14.32, I-
squared=58.1%, P=0.026), so the random-effects model was used to
analyze the data and demonstrated a DFS benefit in favor of
trastuzumab combined with adjuvant chemotherapy as compared to
chemotherapy alone (DCarboT; OR=0.69, 95% CI 0.59–0.80,
P,0.001; Figure S1). The similar result was yielded by the exclusion of
the DCarboT arm in the BCIRG 006 trial (heterogeneity chi-
squared=12.59, I-squared=60.3%, P=0.027; OR=0.67, 95% CI
0.56–0.79, P,0.001; Figure S2).
Overall effects of trastuzumab on secondary outcomes
In terms of the secondary outcomes, there was no between-
study heterogeneity (Table S1) in the ORs for overall survival
(DCarboT; heterogeneity chi-squared=6.13, I-squared=18.5%,
P=0.293), time to locoregional recurrence (heterogeneity chi-
squared=2.87, I-squared=0.0%, P=0.412), time to distant
recurrence (DCarboT; heterogeneity chi-squared=8.30, I-
squared=39.7%, P=0.141), time to contralateral breast cancer
(heterogeneity chi-squared=2.99, I-squared=0.0%, P=0.393),
and time to CNS recurrence (heterogeneity chi-squared=2.61, I-
squared=0.0%, P=0.456).
Through the fixed-effects model, we found that the addition of
trastuzumab to adjuvant chemotherapy elicited a considerable
Table 1. Characteristics of eligible studies included in the meta-analysis.
Study
Median follow-up
(months)
Treatment regimen
per arm
Timing of trastuzumab
initiation with respect
to chemotherapy
Duration of
trastuzumab
administration
(weeks)
Numuber of
patients
BCIRG 006 [10] 65 ACRD - - 1073
ACRD+TRT concurrent 52 1074
D+Carbo+TRT concurrent 52 1075
FinHer [13,14] 62 D/VRFEC - - 116
D/V+TRFEC concurrent 9 115
HERA [7,11,12] 48.4 CT6RTRobservation - - 1698
CT6RTRT61 year sequential 52 1703
CT6RTRT62 years sequential 104 1701
NCCTG N9831 [8,9] 66 ACRP - - 1087
ACRP+TRT concurrent 52 949
ACRPRT sequential 52 1097
NSABP B31 [9] 28.8 ACRP - - 872
ACRP+TRT concurrent 52 864
PACS 04 [15] 47 FEC/ED6RT - - 268
FEC/ED6RTRT sequential 52 260
Abbreviations: BCIRG, Breast Cancer International Research Group; AC, doxorubicin and cyclophosphamide; D, docetaxel; T, trastuzumab; Carbo, carboplatin; FinHer,
Finland HerceptinH study; V, vinorelbine; FEC, fluorouracil, epirubicin and cyclophosphamide; HERA, HerceptinH Adjuvant trial; CT, chemotherapy; RT, radiotherapy;
NCCTG, North Central Cancer Treatment Group; P, paclitaxel; NSABP, National Surgical Adjuvant Breast and Bowel Project; PACS, French Protocol Adjuvant dans le
Cancer du Sein; ED, epirubicin and docetaxel.
doi:10.1371/journal.pone.0021030.t001
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(DCarboT; OR=0.78, 95% CI 0.69–0.88, P,0.001; Figure 1),
locoregional recurrence (OR=0.53, 95% CI 0.44–0.65, P,0.001;
Figure S4) and distant recurrence (DCarboT; OR=0.62, 95% CI
0.55–0.69, P,0.001; Figure 2) rather than for contralateral breast
cancer (OR=1.11, 95% CI 0.61–2.01, P=0.737; Figure S6).
Furthermore, the exclusion of the DCarboT arm failed to
influence the overall results for both overall survival and time to
distant recurrence (Figure S3 and Figure S5).
Unexpectedly, a higher percentage of CNS recurrence was
observed in patients receiving trastuzumab than that in the
observation counterparts (OR=1.58, 95% CI 1.08–2.30,
P=0.018; Table S1 and Figure 3).
Effect of trastuzumab in subgroup by axillary lymph
node (ALN) status
According to the number of ALN involvement, patients were
divided into three subgroups as follows: negative (no ALN involved),
1–3 positive nodes and $4 positive nodes. Compared to chemother-
apy alone, all the subgroups derived a greater benefit in DFS from
trastuzumab in combination with chemotherapy no matter whether
or not the DCarboT arm was included (Figure S7 and Figure S8).
Effect of trastuzumab in subgroup by the timing of
trastuzumab initiation with respect to chemotherapy
According to the timing of trastuzumab initiation with respect to
chemotherapy, patients were categorized into the concurrent or
sequential group. In terms of DFS (Figure S1), time to locoregional
recurrence (Figure S4), time to distant recurrence (Figure 2) and
time to contralateral breast cancer (Figure S6), the effect for each
individual group was consistent with the overall pooled results
(Table S1). Thereinto, whether the DCarboT arm was included or
not did not influence the benefit trend (Table S1) in DFS (Figure
S2) and time to distant recurrence (Figure S5). Interestingly, the
effect of trastuzumab on overall survival and time to CNS
recurrence differed widely between the two groups (Table S1).
Concomitant use of trastuzumab significantly lowered the risk of
mortality (Figure 1) but bore a higher incidence of CNS
recurrence (Figure 3), while statistical significance failed to be
discerned for both overall survival and CNS recurrence in the
Figure 1. Forest plots of OR for the association between trastuzumab administration and overall survival by the timing of
trastuzumab initiation with respect to chemotherapy (including the DCarboT arm of the BCIRG 006 trial). The size of the square box is
proportional to the weight that each study contributes in the meta-analysis. The overall estimate and confidence interval are marked by a diamond.
Symbols on the right of the solid line indicate OR.1 and symbols on the left of the solid line indicate OR,1. Abbreviations: M-H=Mantel-Haenszel
(fixed-effects method); D+L=DerSimonian and Laird (random-effects method).
doi:10.1371/journal.pone.0021030.g001
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aggregated data (Figure 1 and Figure 3).
Publication bias and sensitivity analysis
Either graphical inspection for funnel plots and contour-
enhanced funnel plots or quantitative evaluation from Egger’s
test indicated the absence of publication bias in DFS (DCarboT;
t=20.24, P=0.821; Figure S9), overall survival (DCarboT;
t=0.03, P=0.977), time to locoregional recurrence (t=1.67,
P=0.237), time to distant recurrence (DCarboT; t=0.41,
P=0.701), time to contralateral breast cancer (t=1.31,
P=0.319) and time to CNS recurrence (t=1.86, P=0.204).
What’s more important, the conclusions above on DFS, overall
survival and time to distant recurrence were not substantially
altered by the exclusion of the DCarboT arm (figures and data not
shown). The fail-safe number of missing studies for DFS that
would bring the P-value to .0.05 was 124 and 100 respectively for
the analysis with or without including the DCarboT arm. Similar
results were yielded in terms of overall survival, time to
locoregional recurrence, time to distant recurrence, time to
contralateral breast cancer and time to CNS recurrence (figures
and data not shown).
The sensitivity analyses clarified that no individual study
affected the overall OR for DFS regardless of whether the
DCarboT arm was included or not, since omission of any single
study made no material difference (Figure 4 and Figure S10). The
same conclusions were drawn with respect of overall survival, time
to locoregional recurrence, time to distant recurrence, time to
contralateral breast cancer and time to CNS recurrence (figures
not shown).
Discussion
This analysis is, to the best of our knowledge, the largest and
latest meta-analysis focusing on the administration of trastuzumab
in the adjuvant setting, which incorporated six major randomized
clinical trials with the longest follow-up interval [7–11,13–15]. As
an indispensable component of adjuvant systemic therapy for
HER2-positive early breast cancer patients, trastuzumab has
brought about a considerable decline in the risk of recurrence. In
consistence with previous analyses [17,18], we demonstrated the
beneficial effect of trastuzumab in terms of DFS and time to
distant recurrence. Furthermore, this meta-analysis was the first to
provide substantial evidence for the risk reduction of trastuzumab
in locoregional recurrence. Additionally, the effect of trastuzumab
Figure 2. Forest plots of OR for the association between trastuzumab administration and distant recurrence by the timing of
trastuzumab initiation with respect to chemotherapy (including the DCarboT arm of the BCIRG 006 trial). The size of the square box is
proportional to the weight that each study contributes in the meta-analysis. The overall estimate and confidence interval are marked by a diamond.
Symbols on the right of the solid line indicate OR.1 and symbols on the left of the solid line indicate OR,1. Abbreviations: M-H=Mantel-Haenszel
(fixed-effects method); D+L=DerSimonian and Laird (random-effects method).
doi:10.1371/journal.pone.0021030.g002
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the HERA trial for objective evaluation. In the observation group,
65% patients who were alive and disease free on 16 May 2005
crossed over and received trastuzumab [7,12], which led to a
dilution of treatment efficacy in the ITT analysis. Nevertheless, the
overall pooled OR for all the studies included in this analysis
exhibited a remarkable improvement of overall survival in favor of
trastuzumab. Thus, these data served as a keystone for clinical
practice toward treating HER2-positive early breast cancer patient
with adjuvant trastuzumab.
Another issue merits special attention in this report that there
seemed to be a higher rate of CNS recurrence in patients receiving
adjuvant trastuzumab [17,18]. What brings about this trend still
remains unclear and open to investigation. CNS recurrence is, as a
rule, preceded by metastases to other distant organs such as the
lung, liver or bone since its late occurrence in the natural history of
metastatic breast cancer [19–22]. Therefore, a nonexclusive
hypothesis posits that better control of extracranial diseases with
trastuzumab extended the periods of survival to such a degree as to
display an increased propensity for CNS metastasis [23,24]. As a
result, CNS recurrence will in all likelihood become more
prevalent, which prompts further study on how to prevent its
development and tailor its treatment. Encouragingly, several case
reports have clarified the successful treatment of meningeal
carcinomatosis from breast cancer via intrathecal administration
of trastuzumab [24–27].
Nowadays, much importance has also been attached on the
timing of trastuzumab initiation with respect to chemotherapy.
Among the six largest randomized trials included in this analysis,
the N9831 study was the only one to directly compare the
concurrent and sequential use of trastuzumab. The updated results
ascertained a strong trend for patients with HER2-positive tumors
to derive more benefit in DFS from concomitant trastuzumab
rather than from sequential schedule [8]. In contrast, some
investigators argue that no significant difference in overall survival
was achieved between the two arms despite relative superiority of
concurrent use [28]. Besides, the concurrent arm was temporarily
closed due to its higher frequency of cardiac events than the
sequential and observation peers. For these reasons, they maintain
that it is still far too early to challenge the sequential
administration of trastuzumab in view of both efficacy and safety
[28]. Under such circumstances, it is most urgent for further probe
into what schedule is the better between the concurrent and
sequential use of trastuzumab. Interestingly, the present analysis
first illustrated a significant effect of either concurrent or sequential
trastuzumab on the improvement of DFS and extracranial
Figure 3. Forest plot of OR for the association between trastuzumab administration and CNS recurrence by the timing of
trastuzumab initiation with respect to chemotherapy. The size of the square box is proportional to the weight that each study contributes in
the meta-analysis. The overall estimate and confidence interval are marked by a diamond. Symbols on the right of the solid line indicate OR.1 and
symbols on the left of the solid line indicate OR,1. Abbreviations: M-H=Mantel-Haenszel (fixed-effects method); D+L=DerSimonian and Laird
(random-effects method).
doi:10.1371/journal.pone.0021030.g003
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which had not been previously mentioned [17,18]. Moreover, we
bring it to light for the first time that patients receiving
concomitant trastuzumab experienced a considerable reduction
in mortality risk but a higher incidence of CNS recurrence relative
to those without any trastuzumab treatment, while trastuzumab
administration after completion of adjuvant chemotherapy/
radiotherapy seemed not to notably ameliorate the overall survival
and influence the rate of CNS metastasis. This intriguing
phenomenon further suggests better efficacy of concurrent
schedule than sequential use of trastuzumab. On the other hand,
our findings first provide indirect evidence for the hypothesis just
as mentioned above that superiority of concurrent schedule in
preventing non-CNS recurrence contributes to a relatively
extended life span so that metastatic propensity to CNS, usually
occurring late in the course of the disease, is augmented as a
natural consequence. Nonetheless, our findings are only for
hypothesis generation and need to be confirmed through well-
designed and well-executed randomized clinical trials.
Additionally, we demonstrated unfortunately in the present
analysis that trastuzumab had no bearing on the risk reduction of
contralateral breast cancer. But curiously enough, adjuvant endo-
crine therapy including tamoxifen and aromatase inhibitors brought
about a definite and highly significant decrease in the incidence of
contralateral breast cancer for women with estrogen receptor (ER)-
positive or ER-unknown disease [2,29–31]. As far as we know, this
marked divergence had never been described before; nor had its
underlying mechanism been elucidated. Whether it is attributed to
the dissimilar function in carcinogenesis or metastasis between ER
and HER2 still remains suspended and requires intensive study.
In conclusion, this analysis provides the latest and overwhelm-
ing evidence for the outstanding efficacy of adjuvant trastuzumab
administration in reducing the risk of extracranial recurrence as
well as prolonging the DFS and overall survival. More
importantly, our findings first corroborate that concurrent
trastuzumab outweighs sequential use as concerns overall survival
advantage. Besides, we further certify the postulation that the
rising level of CNS recurrence actually accompanies the life
extension by treatment with trastuzumab vs. observation. Current
fashion of administration might insufficiently maximize the
prophylactic function of trastuzumab on CNS metastasis in the
adjuvant setting rather than increase its incidence. We hypothesize
that the combination of trastuzumab with other targeted agents
easy to penetrate through BBB, such as lapatinib, is likely to
suppress CNS recurrence, which will be partially explained by the
Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisa-
tion (ALTTO) trial in the near future [32]. Therefore, it is
fallacious to reject trastuzumab in the adjuvant setting out of
concerns for CNS metastasis. On the contrary, efforts should be
made to optimize the adjuvant trastuzumab therapy considering
the poor prognosis of HER2-positive breast cancer patients, which
stimulates the closer collaboration of basic, translational and
clinical research for major breakthroughs.
Supporting Information
Figure S1 Forest plots of OR for the association
between trastuzumab administration and DFS by the
timing of trastuzumab initiation with respect to chemo-
therapy (including the DCarboT arm of the BCIRG 006
trial). The size of the square box is proportional to the weight
that each study contributes in the meta-analysis. The overall
estimate and confidence interval are marked by a diamond.
Symbols on the right of the solid line indicate OR.1 and symbols
Figure 4. Sensitivity analyses for the influence of individual studies on the summary OR for the association between trastuzumab
administration and DFS (including the DCarboT arm of the BCIRG 006 trial). The vertical midline indicates the overall OR and the lateral
vertical lines indicate its 95% CI. Every hollow round indicates the pooled OR when the left study is omitted in this meta-analysis. The two ends of
every dotted line represent the respective 95% CI.
doi:10.1371/journal.pone.0021030.g004
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H=Mantel-Haenszel (fixed-effects method); D+L=DerSimonian
and Laird (random-effects method).
(TIF)
Figure S2 Forest plots of OR for the association
between trastuzumab administration and DFS by the
timing of trastuzumab initiation with respect to chemo-
therapy without including the DCarboT arm of the
BCIRG 006 trial. The size of the square box is proportional to
the weight that each study contributes in the meta-analysis. The
overall estimate and confidence interval are marked by a diamond.
Symbols on the right of the solid line indicate OR.1 and symbols
on the left of the solid line indicate OR,1. Abbreviations: M-
H=Mantel-Haenszel (fixed-effects method); D+L=DerSimonian
and Laird (random-effects method).
(TIF)
Figure S3 Forest plots of OR for the association
between trastuzumab administration and overall sur-
vival by the timing of trastuzumab initiation with
respect to chemotherapy without including the DCarboT
arm of the BCIRG 006 trial. The size of the square box is
proportional to the weight that each study contributes in the meta-
analysis. The overall estimate and confidence interval are marked
by a diamond. Symbols on the right of the solid line indicate
OR.1 and symbols on the left of the solid line indicate OR,1.
Abbreviations: M-H=Mantel-Haenszel (fixed-effects method);
D+L=DerSimonian and Laird (random-effects method).
(TIF)
Figure S4 Forest plot of OR for the association between
trastuzumab administration and locoregional recur-
rence by the timing of trastuzumab initiation with
respect to chemotherapy. The size of the square box is
proportional to the weight that each study contributes in the meta-
analysis. The overall estimate and confidence interval are marked
by a diamond. Symbols on the right of the solid line indicate
OR.1 and symbols on the left of the solid line indicate OR,1.
Abbreviations: M-H=Mantel-Haenszel (fixed-effects method);
D+L=DerSimonian and Laird (random-effects method).
(TIF)
Figure S5 Forest plots of OR for the association
between trastuzumab administration and distant recur-
rence by the timing of trastuzumab initiation with
respect to chemotherapy without including the DCarboT
arm of the BCIRG 006 trial. The size of the square box is
proportional to the weight that each study contributes in the meta-
analysis. The overall estimate and confidence interval are marked
by a diamond. Symbols on the right of the solid line indicate
OR.1 and symbols on the left of the solid line indicate OR,1.
Abbreviations: M-H=Mantel-Haenszel (fixed-effects method);
D+L=DerSimonian and Laird (random-effects method).
(TIF)
Figure S6 Forest plot of OR for the association between
trastuzumab administration and contralateral breast
cancer by the timing of trastuzumab initiation with
respect to chemotherapy. The size of the square box is
proportional to the weight that each study contributes in the meta-
analysis. The overall estimate and confidence interval are marked
by a diamond. Symbols on the right of the solid line indicate
OR.1 and symbols on the left of the solid line indicate OR,1.
Abbreviations: M-H=Mantel-Haenszel (fixed-effects method);
D+L=DerSimonian and Laird (random-effects method).
(TIF)
Figure S7 Forest plots of OR for the association
between trastuzumab administration and DFS by axil-
lary lymph node status (including the DCarboT arm of
the BCIRG 006 trial). The size of the square box is
proportional to the weight that each study contributes in the
meta-analysis. The overall estimate and confidence interval are
marked by a diamond. Symbols on the right of the solid line
indicate OR.1 and symbols on the left of the solid line indicate
OR,1. Abbreviations: M-H=Mantel-Haenszel (fixed-effects
method); D+L=DerSimonian and Laird (random-effects method).
(TIF)
Figure S8 Forest plots of OR for the association
between trastuzumab administration and DFS by axil-
lary lymph node status without including the DCarboT
arm of the BCIRG 006 trial. The size of the square box is
proportional to the weight that each study contributes in the meta-
analysis. The overall estimate and confidence interval are marked
by a diamond. Symbols on the right of the solid line indicate
OR.1 and symbols on the left of the solid line indicate OR,1.
Abbreviations: M-H=Mantel-Haenszel (fixed-effects method);
D+L=DerSimonian and Laird (random-effects method).
(TIF)
Figure S9 Funnel plot for publication bias in DFS with
the analysis including the DCarboT arm of the BCIRG
006 trial. The red line indicates the fitted line corresponding to
the Egger’s regression test for funnel plot asymmetry.
(TIF)
Figure S10 Sensitivity analyses for the influence of
individual studies on the summary OR for the associa-
tion between trastuzumab administration and DFS
without including the DCarboT arm of the BCIRG 006
trial. The vertical midline indicates the overall OR and the
lateral vertical lines indicate its 95% CI. Every hollow round
indicates the pooled OR when the left study is omitted in this
meta-analysis. The two ends of every dotted line represent the
respective 95% CI.
(TIF)
Table S1 Effect of trastuzumab in subgroup by the
timing of trastuzumab initiation with respect to adju-
vant chemotherapy.
(DOC)
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